Sign in

RZLT on Nasdaq

Rezolute, Inc.

American pharmaceutical preparations company based in Redwood City2

In its 2026 annual report the company says: “Rezolute, Inc. is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.”5 Its shares trade on Nasdaq under the symbol RZLT.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$77.6MNet income, fiscal 20263

Compare with another stock.

  • TickerRZLT on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersRedwood City, United States2
  • Incorporated inNV4
  • Business address275 Shoreline Drive, Suite 500, Redwood City, Ca 940654
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI549300T05L48T72P2G082
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE COMPANY CORPORATION, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 52688222

See how the biggest companies compare on our leaderboards

Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-77.1%Return on equity3

Financial statements

Operating income678910113-$83.0M in 2026+220% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$25.9M-$25.9M20192020: -$20.5M-$20.5M2020−21%2021: -$22.9M-$22.9M2021+12%2022: -$41.8M-$41.8M2022+83%2023: -$56.0M-$56.0M2023+34%2024: -$70.4M-$70.4M2024+26%2025: -$79.9M-$79.9M2025+13%2026: -$83.0M-$83.0M2026+4%
Net income678910113-$77.6M in 2026+155% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$30.4M-$30.4M20192020: -$20.3M-$20.3M2020−33%2021: -$20.9M-$20.9M2021+3%2022: -$41.1M-$41.1M2022+96%2023: -$51.8M-$51.8M2023+26%2024: -$68.5M-$68.5M2024+32%2025: -$74.4M-$74.4M2025+9%2026: -$77.6M-$77.6M2026+4%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-06-302025-06-30
Research and development$53.8M$61.5M
General and administrative$29.2M$18.4M
Total operating expenses$83.0M$79.9M
Operating loss-$83.0M-$79.9M
Interest and other income, net$5.4M$5.5M
Net loss-$77.6M-$74.4M
Net unrealized gain (loss) on marketable debt securities-$112.0K$72.0K
Comprehensive loss-$77.7M-$74.3M
Net loss per common share - basic (in dollars per share)-$0.75-$0.98
Net loss per common share - diluted (in dollars per share)-$0.75-$0.98
Weighted average shares outstanding - basic (in shares)103.9M shares76.0M shares
Weighted average shares outstanding - diluted (in shares)103.9M shares76.0M shares

Compare Rezolute, Inc. with another company

Corporate structure

Rezolute, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Rezolute, Inc.

  • Rezolute, Inc. Redwood City, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Rezolute, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$210.0K3 Jun 30, 2026$210.0K3 Jun 30, 20250%
Accumulated depreciation$169.0K3 Jun 30, 2026$138.0K3 Jun 30, 2025+22.5%
Property and equipment, net$41.0K3 Jun 30, 2026$72.0K3 Jun 30, 2025−43.1%
Operating-lease assets (leased space)$769.0K3 Jun 30, 2026$1.3M3 Jun 30, 2025−43.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.6M3 Jun 30, 2026$94.1M3 Jun 30, 2025−88.7%
Marketable securities, current$97.2M3 Jun 30, 2026$73.8M3 Jun 30, 2025+31.8%

Properties, in its own words

In April 2022, we entered into a lease for a corporate headquarters facility at 275 Shoreline Drive, Suite 500, Redwood City California 94065. The leased space contains approximately 9,300 square feet of office space. The lease commenced in October 2022 and provides for average remaining monthly rent payments of approximately $53,000 through October 2027.

In November 2020, we entered into a lease in Bend, Oregon where the leased space consists of approximately 5,000 square feet of office space. In October 2023, we entered into a lease extension for this space, which provides for monthly rent payments of approximately $9,000 through February 2027.

The rest of Item 2

We believe our current physical properties are sufficient and adequate to meet our current and projected requirements.

Item 2 of the 10-K filed Sep 24, 2026.5

Leadership

Who has led Rezolute, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nevan C. Elam2013–now

Chair

  1. Hoyoung Huh2017

President

  1. Nir Bar2011–2012

Chief financial officer

  1. Keith A. Vendola2018–2019
  2. Daron Evans2024–now
201520202025
Board members and other officers (16)

Former names

  • AntriaBio, Inc.Dec 11, 2012 to Dec 7, 20174
  • FITS MY STYLE INCMay 17, 2011 to Jan 11, 20134

Timeline

  1. Oct 14, 20268-K Regulation FD disclosure35
  2. Oct 5, 20268-K Regulation FD disclosure36
  3. Sep 24, 20268-K Results of operations37
  4. Jun 2, 20268-K Regulation FD disclosure38
  5. May 12, 20268-K Results of operations39
  6. May 4, 20268-K Regulation FD disclosure40
  7. Mar 24, 20268-K Regulation FD disclosure41
  8. Feb 12, 20268-K Results of operations42
  9. Jan 7, 20268-K Regulation FD disclosure43
  10. Nov 21, 20258-K Shareholder vote44
  11. Nov 12, 20258-K Regulation FD disclosure45
  12. Nov 6, 20258-K Results of operations46
  13. Feb 8, 2013New chief executive Nevan C. Elam becomes CEO16

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.18) a share, on Nov 6, 2025.47

When it reported results

  1. Sep 24, 2026Reported quarterly or annual results37
  2. May 12, 2026Reported quarterly or annual results39
  3. Feb 12, 2026Reported quarterly or annual results42
  4. Nov 6, 2025Reported quarterly or annual results46
  5. Sep 17, 2025Reported quarterly or annual results48
  6. May 13, 2025Reported quarterly or annual results49
  7. Feb 12, 2025Reported quarterly or annual results50
  8. Nov 7, 2024Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

274 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 74 major events, 94 insider forms, 39 large holders, 47 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Oct 7, 2026PRE 14A EDGAR
  3. Oct 5, 20268-K EDGAR
  4. Sep 24, 202610-K EDGAR
  5. Sep 24, 20268-K EDGAR
  6. Sep 3, 20264 EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 12, 2026SCHEDULE 13G EDGAR
  9. Aug 12, 2026SCHEDULE 13G/A EDGAR
  10. Jul 7, 20264 EDGAR
  11. Jul 7, 20264 EDGAR
  12. Jul 7, 20264 EDGAR
  13. Jun 2, 20268-K EDGAR
  14. May 15, 2026SCHEDULE 13G EDGAR
  15. May 12, 202610-Q EDGAR
  16. May 12, 20268-K EDGAR
  17. May 11, 2026SCHEDULE 13G/A EDGAR
  18. May 4, 20268-K EDGAR
  19. Mar 31, 20264 EDGAR
  20. Mar 26, 2026SCHEDULE 13G/A EDGAR

The 274 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 50 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 30, 2026Evans DaronCFOBuy10,000$2.85$28.5KForm 4
Dec 16, 2025Hogenhuis WladimirDirectorBuy5,650$1.69$9.5KForm 4
Dec 16, 2025ROBERTS BRIAN KENNETHChief Medical OfficerBuy28,000$1.70$47.6KForm 4
Dec 15, 2025Evans DaronCFOBuy45,000$1.77$79.8KForm 4
Dec 15, 2025Elam Nevan CCEOBuy32,000$1.59$50.9KForm 4
Dec 15, 2025Karnawat Sunil RatilalChief Commercial OfficerBuy12,100$1.62$19.6KForm 4
Dec 9, 2025Evans DaronCFOBuy10,549$5.04$53.2KForm 4
Jun 25, 2025ROBERTS BRIAN KENNETHChief Medical OfficerBuy2,500$4.38$10.9KForm 4
Jun 24, 2025Evans DaronCFOBuy5,000$4.05$20.2KForm 4
Jun 13, 2025Kim Young-JinDirectorBuy1,230,769$3.25$4.0MForm 4
Jun 13, 2025KREHER NERISSADirectorBuy3,076$3.25$10.0KForm 4
Mar 31, 2025Hogenhuis WladimirDirectorBuy6,758$2.92$19.7KForm 4
Mar 27, 2025Elam Nevan CCEOBuy12,302$2.85$35.1KForm 4
Mar 26, 2025Evans DaronCFOBuy20,000$2.88$57.7KForm 4
Feb 18, 2025Hogenhuis WladimirDirectorBuy10,000$4.70$47.0KForm 4
Dec 18, 2024Evans DaronCFOBuy10,000$4.29$42.9KForm 4
Dec 12, 2024Evans DaronCFOBuy9,000$4.60$41.4KForm 4
Sep 24, 2024Hogenhuis WladimirDirectorBuy4,259$4.70$20.0KForm 4
Jun 25, 2024Kim Young-JinDirectorBuy1,250,000$4.00$5.0MForm 4
Jun 25, 2024Hogenhuis WladimirDirectorBuy4,815$4.15$20.0KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Nevan Charles Elam57$610.8K$2.9M70
2025Daron Evans52$421.5K$1.7M70
2025Brian RobertsM.D.51$483.4K$1.4M70
2025Sunil Karnawat58$12$1270
2024Chief Executive Officer$550.2K$1.2M70
2024Chief Medical Officer$471.6K$818.0K70
2024Chief Financial Officer$121.3K$384.1K70
2024Chief Commercial Officer$12$1270

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Federated Hermes, Inc.12,990,659$67.6M0.1%No change
Ra Capital Management, L.P.9,445,039$49.1M0.4%+265,039
BlackRock, Inc.7,718,291$40.1M0.0%+1,404,788
Opaleye Management Inc.6,300,000$32.8M3.0%No change
Balyasny Asset Management L.P.4,662,039$24.2M0.0%−386,382
Vanguard Capital Management LLC3,835,827$19.9M0.0%+313,747
Siren, L.L.C.3,328,287$17.3M0.4%No change
Jacobs Levy Equity Management, Inc2,561,654$13.3M0.0%+2,341,247
Jennison Associates LLC2,459,308$12.8M0.0%−979,573
Geode Capital Management, LLC2,170,154$11.3M0.0%+205,795
State Street Corp1,850,128$9.6M0.0%+78,287
D. E. Shaw & Co., Inc.1,839,357$9.6M0.0%+73,377
Morgan Stanley1,618,783$8.4M0.0%−1,128,888
Vanguard Portfolio Management LLC1,380,746$7.2M0.0%−1,601,019
Goldman Sachs Group Inc1,316,782$6.8M0.0%+714,486
Nuveen, LLC1,295,209$6.7M0.0%+1,197,523
Kennedy Capital Management LLC1,221,678$6.4M0.1%−14,420
Blackstone Inc.1,082,927$5.6M0.0%New
Aqr Capital Management LLC1,007,962$5.2M0.0%+211,266
Affinity Asset Advisors, LLC1,000,000$5.2M0.3%−547,641
Great Point Partners LLC951,809$4.9M1.2%No change
Ikarian Capital, LLC935,012$4.9M0.8%+918,533
Dimensional Fund Advisors LP890,733$4.6M0.0%+360,504
22nw, LP820,653$4.3M4.1%No change
Velan Capital Investment Management LP750,000$3.9M2.4%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Rezolute, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRezolute, Inc.1
  • CIK0001509261
  • Employer ID (EIN)27-34408945
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inNevada5
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address275 Shoreline Drive, Suite 500, Redwood City, CA 940651
  • Phone650-206-45071
  • Shares outstanding96,722,333 shares as of Sep 21, 20265
  • Public float$203.9M as of Dec 31, 20255
  • AuditorGRANT THORNTON LLP, Newport Beach, California PCAOB ID 248; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMay 17, 20111
  • Filings751 in all: 8-K (182), 4 (172), 10-Q (45), 3 (31), 424B3 (31), EFFECT (29), CORRESP (25), UPLOAD (25)1
    All 49 form types

    SC 13G/A (17), 10-K (16), POS AM (14), D (12), S-1/A (12), SC 13D (12), 424B5 (11), SC 13G (10), DEF 14A (9), S-1 (9), SCHEDULE 13G (9), SCHEDULE 13G/A (9), PRE 14A (7), S-3 (7), D/A (4), NT 10-K (4), S-3/A (4), S-8 (4), SC 13D/A (4), 10-K/A (3), 4/A (3), CT ORDER (3), PRER14A (3), 8-K/A (2), DEF 14C (2), DEFA14A (2), PRE 14C (2), PRER14C (2), SC 14F1 (2), SC TO-I/A (2), 10-Q/A (1), 3/A (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), 8-K12B (1), CERT (1), NT 10-Q (1), RW (1), S-3ASR (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Sep 24, 2026
    Quarterly report (10-Q) May 12, 2026
    Proxy statement (DEF 14A) Oct 7, 2025
    Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001RZLTNasdaq

From the cover page of the 10-K filed Sep 24, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Rezolute, Inc. names in Item 1A of its 10-K filed Sep 24, 2026: 32 risks under these headings, as written.5

  • Investors should consider carefully the following risks before deciding to purchase any of our securities. If any of the events or developments described below actually occur, our business, results of operations and financial condition would likely suffer and investors may lose all or part of their investment. In addition, it is also possible that other risks and uncertainties that affect our business may arise or become material in the future.
  • Risks Related to Our Product Development and Commercialization
  • The supplemental information provided to the FDA to support our belief in the effectiveness of ersodetug in the treatment of congenital HI might not result in a viable path forward.
  • There is no guarantee that the FDA will not consider the results of the sunRIZE trial when it considers additional regulatory steps related to ersodetug and its treatment of other conditions.
  • If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.
  • Interim, “topline” and preliminary data from clinical trials may change as more data become available, are not necessarily predictive of the final results of the completed study or the results of other ongoing or future studies and are subject to audit and verification procedures that could result in material changes.
  • Modifications to the upLIFT trial may fail to produce effective results.
  • Any delays in the commencement or completion, or termination or suspension, of our future clinical trials, if any, could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • Adverse events in our clinical trials may force us to stop development of our product candidates or prevent regulatory approval of our product candidates.
  • We are exposed to additional risks associated with regulatory approval.
  • The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.
  • Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from ever generating meaningful revenues or achieving profitability.
The other 21 risks
  • Due to our reliance on contract research organizations or other third parties to conduct clinical trials, we may not have complete control over the timing, conduct and expense of our clinical trials.
  • Any failure or delay by our third-party suppliers on which we rely or intend to rely to provide materials necessary to develop and manufacture our drug products may delay or impair our ability to commercialize our product candidates.
  • We may be unable to manage our anticipated growth effectively.
  • If we use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • Risks Related to Our Business
  • Failure of our clinical trials could expose us to litigation and other legal claims, which could materially and adversely affect our business, financial condition and results of operations.
  • We have a long history of losses and may not achieve profitability in the future. We will need substantial additional capital to fund our operations. If we fail to obtain additional capital, we will be unable to sustain operations.
  • We face potential product liability exposure, and, if successful claims are brought against us, we may incur substantial liability.
  • We may not be able to use a significant portion of our net operating loss carryforwards, which could adversely affect our profitability.
  • If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.
  • In the future, we may no longer qualify as a smaller reporting company or non-accelerated filer, which could increase our compliance costs and reporting obligations.
  • Our collection, use, processing, and cross-border transfer of personal information, including individually identifiable health information, is governed by restrictive regulations.
  • We could recognize losses on securities held in our marketable debt securities portfolio, particularly if interest rates increase or economic and market conditions deteriorate.
  • Unfavorable global and regional economic and political conditions could adversely affect our business, financial condition or results of operations.
  • Certain Provisions of Nevada law may have anti-takeover effects.
  • Risks Related to Our Intellectual Property
  • Our current patent positions and license portfolio may not include all patent rights needed for the full development and commercialization of our product candidates. We cannot be sure that patent rights we may need in the future will be available to license on commercially reasonable terms, or at all.
  • If our or our licensors’ patent positions do not adequately protect our product candidates or any future products, others could compete with us more directly, which would harm our business.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • Litigation regarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing product candidates to market and harm our ability to operate.
  • If our patent and other intellectual property protection is inadequate, future sales and profits may never materialize or competitors could force our products completely out of the market.
  • Risks Related to Our Common Stock
  • Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.
  • Investor relations activities and supply and demand factors may affect the price of our common stock.

Legal proceedings

For a discussion of the Company’s legal proceedings, please refer to the discussion under the caption “Notes to Consolidated Financial Statements - Commitments and Contingencies” in Part II. Item 8 of this Annual Report.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70